肿瘤专科临床药师在多学科协作诊疗模式中的作用研究进展
摘要
目的:了解肿瘤专科临床药师在多学科协作(MDT)诊疗模式中的作用,为MDT的进一步开展提供参考。方法:以"肿瘤""临床药师""药师""多学科协作""Tumor""Cancer""Pharmacist""Clinical pharmacist""MDT""Multidisciplinary team""Multidisciplinary treatment"等为检索词,对Web of Science、Embase、PubMed、中国知网、万方、维普等数据库中收录的文献进行组合检索,检索时限均为建库起至2018年1月。就国内外肿瘤专科临床药师参与肿瘤MDT诊疗及其作用的研究进展进行归纳与总结。结果与结论:共检索到相关文献142篇,其中有效文献34篇。在MDT诊疗模式中,肿瘤专科临床药师借助自身药学专业优势,通过药学干预、个体化用药等方式参与住院患者的药物治疗,通过药物重整、用药教育、协助开展肿瘤姑息治疗门诊、口服化疗药物管理等方式参与院外患者的药物治疗,以提高患者的用药依从性;同时,肿瘤专科临床药师还通过参与建立计算机医嘱录入系统、参与制订和推广院内相关标准/指南、参与细胞免疫治疗临床试验、进行不良反应监测等方式来提高处方审核的效率以及用药的合理性。
引文
[1]LAMB BW,TAYLOR C,LAMB JN,et al.Facilitators and barriers to teamworking and patient centeredness in multidisciplinary cancer teams:findings of a national study[J].Ann Surg Oncol,2013,20(5):1408-1416.
[2]SONG P,WU Q,HUANG Y.Multidisciplinary team and team oncology medicine research and development in China[J].Biosci Trends,2010,4(4):151-160.
[3]LAMB BW,JALIL RT,SEVDALIS N,et al.Strategies to improve the efficiency and utility of multidisciplinary team meetings in urology cancer care:a survey study[J].BMC Health Serv Res,2014.DOI:10.1186/1472-6963-14-377.
[4]国家卫生和计划生育委员会.关于加强肿瘤规范化诊疗管理工作的通知[EB/OL].(2016-03-22)[2018-07-24].http://www.nhfpc.gov.cn/yzygj/s2911/201603/6ab1c14963acceb5d1f37540df.shtml.
[5]National Comprehensive Cancer Network.Clinical practice guidelines in oncology.older adult oncology,version 1:2018[EB/OL].(2018-06-11)[2018-07-24].https://www.nccn.org/professionals/physician_gls/default.aspx#senior.
[6]AVERY M,WILLIAMS F.The importance of pharmacist providing patient education in oncology[J].J Pharm Pract,2015,28(1):26-30.
[7]TAYLOR C,BROWN K,LAMB B,et al.Developing and testing TEAM(team evaluation and assessment measure),a self-assessment tool to improve cancer multidisciplinary teamwork[J].Ann Surg Oncol,2012,19(13):4019-4027.
[8]Minsky BD.Multidisciplinary case teams:an approach to the future management of advanced colorectal cancer[J].Br J Cancer,1998,77(2):1-4.
[9]汪晓东,李立.结直肠肿瘤多学科协作诊治模式下人员构架的探索与实践[J].中国普外基础与临床杂志,2007,14(2):235-238.
[10]邢沫,王凤玲,王丹.我院建立肿瘤多学科诊疗模式的探讨[J].中国医院管理,2015,35(6):29-31.
[11]LI E,SCHLEIF R,EDELEN B.Hospital management of outpatient oncology treatment decisions:a survey to identify strategies and concerns[J].J Oncol Pract,2013,9(5):e248-e254.
[12]HOLLE LM,HARRIS CS,CHAN A,et al.Pharmacists’roles in oncology pharmacy services:results of a global survey[J].J Oncol Pharm Pract,2017,23(3):185-194.
[13]AZIZ MT,REHMAN TU,QURESHI S,et al.Effects of multidisciplinary teams and an integrated follow-up electronic system on clinical pharmacist interventions in a cancer hospital[J].Int J Clin Pharm,2017,39(6):1175-1184.
[14]LOPEZ-MARTIN C,GARRIDO SILES M,ALCAIDE-GARCIA J,et al.Role of clinical pharmacists to prevent drug interactions in cancer outpatients:a single-centre experience[J].Int J Clin Pharm,2014,36(6):1251-1259.
[15]SERRANO-FABIáA,ALBERT-MARíA,ALMENAR-CUBELLS D,et al.Multidisciplinary system for detecting medication errors in antineoplastic chemotherapy[J].J Oncol Pharm Pract,2010,16(2):105-112.
[16]王伟兰,郭代红,朱曼,等.肿瘤专科临床药师与医护团队协作模式探讨[J].药学服务与研究,2013,13(3):213-215.
[17]FADOL AP,LECH T,BICKFORD C,et al.Pregnancy in a patient with cancer and heart failure:challenges and complexities[J].J Adv Pract Oncol,2012,3(2):85-93.
[18]HO L,AKADA K,MESSNER H,et al.Pharmacist’s role in improving medication safety for patients in an allogeneic hematopoietic cell transplant ambulatory clinic[J].Can J Hosp Pharm,2013,66(2):110-117.
[19]MANCINI R.Implementing a standardized pharmacist assessment and evaluating the role of a pharmacist in a multidisciplinary supportive oncology clinic[J].J Support Oncol,2012,10(3):99-106.
[20]CARCELERO E,ANGLADA H,TUSET M,et al.Interactions between oral antineoplastic agents and concomitant medication:a systematic review[J].Expert Opin Drug Saf,2013,12(3):403-420.
[21]NEUSS MN,POLOVICH M,MCNIFF K,et al.2013 updated American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards including standards for the safe administration and management of oral chemotherapy[J].J Oncol Pract,2013,9(2 Suppl):5s-13s.
[22]SHAH NN,CASELLA E,CAPOZZI D,et al.Improving the safety of oral chemotherapy at an academic medical center[J].J Oncol Practice,2016,12(1):e71-e76.
[23]MARIN D,BAZEOS A,MAHON FX,et al.Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib[J].J Clin Oncol,2010,28(14):2381-2388.
[24]LAM MS,CHEUNG N.Impact of oncology pharmacistmanaged oral anticancer therapy in patients with chronic myelogenous leukemia[J].J Oncol Pharm Pract,2016,22(6):741-748.
[25]ZERILLO JA,GOLDENBERG BA,KOTECHA RR,et al.Interventions to improve oral chemotherapy safety and quality:a systematic review[J].JAMA Oncol,2018,4(1):105-117.
[26]HOLLE LM,PURI S,CLEMENT JM.Physician-pharmacist collaboration for oral chemotherapy monitoring:Insights from an academic genitourinary oncology practice[J].J Oncol Pharm Pract,2016,22(3):511-516.
[27]COLLINS CM,ELSAID KA.Using an enhanced oral chemotherapy computerized provider order entry system to reduce prescribing errors and improve safety[J].Int J Qual Health Care,2011,23(1):36-43.
[28]AKAZA H.What is the Asian consensus statement on NCCN clinical practice guidelines in oncology(NCCN-ACS)?[J].Jpn J Clin Oncol,2016,46(4):299-302.
[29]PERWITASARI DAI,GELDERBLOM H,Atthobari J,et al.Anti-emetic drugs in oncology:pharmacology and individualization by pharmacogenetics[J].Int J Clin Pharm,2011,33(1):33-43.
[30]ZAIDAN M,SOUFI L,HAFEEZ M,et al.Assessing prescribing patterns for the prevention of chemotherapy-induced nausea and vomiting in the national center for cancer care and research[J].Saudi Pharma J,2015,23(4):381-387.
[31]ANDREYEV HJ,DAVIDSON SE,GILLESPIE C,et al.Practice guidance on the management of acute and chronic gastrointestinal problems arising as a result of treatment for cancer[J].Gut,2012,61(2):179-192.
[32]ANDREYEV J,ROSS P,DONNELLAN C,et al.Guidance on the management of diarrhoea during cancer chemotherapy[J].Lancet Oncol,2014,15(10):e447-e460.
[33]MUHAMMAD N,MAO Q,XIA H.CAR T-cells for cancer therapy[J].Biotechnol Genet Eng Rev,2017,33(2):190-226.
[34]MCGUIRK J,WALLER EK,QAYED M,et al.Building blocks for institutional preparation of CTL019 delivery[J].Cytotherapy,2017,19(9):1015-1024.
[2]SONG P,WU Q,HUANG Y.Multidisciplinary team and team oncology medicine research and development in China[J].Biosci Trends,2010,4(4):151-160.
[3]LAMB BW,JALIL RT,SEVDALIS N,et al.Strategies to improve the efficiency and utility of multidisciplinary team meetings in urology cancer care:a survey study[J].BMC Health Serv Res,2014.DOI:10.1186/1472-6963-14-377.
[4]国家卫生和计划生育委员会.关于加强肿瘤规范化诊疗管理工作的通知[EB/OL].(2016-03-22)[2018-07-24].http://www.nhfpc.gov.cn/yzygj/s2911/201603/6ab1c14963acceb5d1f37540df.shtml.
[5]National Comprehensive Cancer Network.Clinical practice guidelines in oncology.older adult oncology,version 1:2018[EB/OL].(2018-06-11)[2018-07-24].https://www.nccn.org/professionals/physician_gls/default.aspx#senior.
[6]AVERY M,WILLIAMS F.The importance of pharmacist providing patient education in oncology[J].J Pharm Pract,2015,28(1):26-30.
[7]TAYLOR C,BROWN K,LAMB B,et al.Developing and testing TEAM(team evaluation and assessment measure),a self-assessment tool to improve cancer multidisciplinary teamwork[J].Ann Surg Oncol,2012,19(13):4019-4027.
[8]Minsky BD.Multidisciplinary case teams:an approach to the future management of advanced colorectal cancer[J].Br J Cancer,1998,77(2):1-4.
[9]汪晓东,李立.结直肠肿瘤多学科协作诊治模式下人员构架的探索与实践[J].中国普外基础与临床杂志,2007,14(2):235-238.
[10]邢沫,王凤玲,王丹.我院建立肿瘤多学科诊疗模式的探讨[J].中国医院管理,2015,35(6):29-31.
[11]LI E,SCHLEIF R,EDELEN B.Hospital management of outpatient oncology treatment decisions:a survey to identify strategies and concerns[J].J Oncol Pract,2013,9(5):e248-e254.
[12]HOLLE LM,HARRIS CS,CHAN A,et al.Pharmacists’roles in oncology pharmacy services:results of a global survey[J].J Oncol Pharm Pract,2017,23(3):185-194.
[13]AZIZ MT,REHMAN TU,QURESHI S,et al.Effects of multidisciplinary teams and an integrated follow-up electronic system on clinical pharmacist interventions in a cancer hospital[J].Int J Clin Pharm,2017,39(6):1175-1184.
[14]LOPEZ-MARTIN C,GARRIDO SILES M,ALCAIDE-GARCIA J,et al.Role of clinical pharmacists to prevent drug interactions in cancer outpatients:a single-centre experience[J].Int J Clin Pharm,2014,36(6):1251-1259.
[15]SERRANO-FABIáA,ALBERT-MARíA,ALMENAR-CUBELLS D,et al.Multidisciplinary system for detecting medication errors in antineoplastic chemotherapy[J].J Oncol Pharm Pract,2010,16(2):105-112.
[16]王伟兰,郭代红,朱曼,等.肿瘤专科临床药师与医护团队协作模式探讨[J].药学服务与研究,2013,13(3):213-215.
[17]FADOL AP,LECH T,BICKFORD C,et al.Pregnancy in a patient with cancer and heart failure:challenges and complexities[J].J Adv Pract Oncol,2012,3(2):85-93.
[18]HO L,AKADA K,MESSNER H,et al.Pharmacist’s role in improving medication safety for patients in an allogeneic hematopoietic cell transplant ambulatory clinic[J].Can J Hosp Pharm,2013,66(2):110-117.
[19]MANCINI R.Implementing a standardized pharmacist assessment and evaluating the role of a pharmacist in a multidisciplinary supportive oncology clinic[J].J Support Oncol,2012,10(3):99-106.
[20]CARCELERO E,ANGLADA H,TUSET M,et al.Interactions between oral antineoplastic agents and concomitant medication:a systematic review[J].Expert Opin Drug Saf,2013,12(3):403-420.
[21]NEUSS MN,POLOVICH M,MCNIFF K,et al.2013 updated American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards including standards for the safe administration and management of oral chemotherapy[J].J Oncol Pract,2013,9(2 Suppl):5s-13s.
[22]SHAH NN,CASELLA E,CAPOZZI D,et al.Improving the safety of oral chemotherapy at an academic medical center[J].J Oncol Practice,2016,12(1):e71-e76.
[23]MARIN D,BAZEOS A,MAHON FX,et al.Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib[J].J Clin Oncol,2010,28(14):2381-2388.
[24]LAM MS,CHEUNG N.Impact of oncology pharmacistmanaged oral anticancer therapy in patients with chronic myelogenous leukemia[J].J Oncol Pharm Pract,2016,22(6):741-748.
[25]ZERILLO JA,GOLDENBERG BA,KOTECHA RR,et al.Interventions to improve oral chemotherapy safety and quality:a systematic review[J].JAMA Oncol,2018,4(1):105-117.
[26]HOLLE LM,PURI S,CLEMENT JM.Physician-pharmacist collaboration for oral chemotherapy monitoring:Insights from an academic genitourinary oncology practice[J].J Oncol Pharm Pract,2016,22(3):511-516.
[27]COLLINS CM,ELSAID KA.Using an enhanced oral chemotherapy computerized provider order entry system to reduce prescribing errors and improve safety[J].Int J Qual Health Care,2011,23(1):36-43.
[28]AKAZA H.What is the Asian consensus statement on NCCN clinical practice guidelines in oncology(NCCN-ACS)?[J].Jpn J Clin Oncol,2016,46(4):299-302.
[29]PERWITASARI DAI,GELDERBLOM H,Atthobari J,et al.Anti-emetic drugs in oncology:pharmacology and individualization by pharmacogenetics[J].Int J Clin Pharm,2011,33(1):33-43.
[30]ZAIDAN M,SOUFI L,HAFEEZ M,et al.Assessing prescribing patterns for the prevention of chemotherapy-induced nausea and vomiting in the national center for cancer care and research[J].Saudi Pharma J,2015,23(4):381-387.
[31]ANDREYEV HJ,DAVIDSON SE,GILLESPIE C,et al.Practice guidance on the management of acute and chronic gastrointestinal problems arising as a result of treatment for cancer[J].Gut,2012,61(2):179-192.
[32]ANDREYEV J,ROSS P,DONNELLAN C,et al.Guidance on the management of diarrhoea during cancer chemotherapy[J].Lancet Oncol,2014,15(10):e447-e460.
[33]MUHAMMAD N,MAO Q,XIA H.CAR T-cells for cancer therapy[J].Biotechnol Genet Eng Rev,2017,33(2):190-226.
[34]MCGUIRK J,WALLER EK,QAYED M,et al.Building blocks for institutional preparation of CTL019 delivery[J].Cytotherapy,2017,19(9):1015-1024.